← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCBiologicstaleBioNTech SEPhase 2

BNT326 (BNT326)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin frozen liquid)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 34%임상시험 2상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, Venetoclax)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
AntibodystaleAmgenPhase 2

Bemarituzumab (Bemarituzumab)

Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 46.8%임상시험 2상태 ACTIVE
AntibodystaleRocheApproved

Bevacizumab Injection [Avastin] (Bevacizumab Injection [Avastin])

Retinal Neovascularization; Macular Edema · Retinal Neovascularization

#RetinalNeovascularization#Antibody#Approved#항체#면역항체+3
임상시험 2상태 ACTIVE
AntibodystaleAmgenPhase 2

MT103 (Blinatumomab, Blinatumomab (MT103))

Non-Hodgkin's Lymphoma, Relapsed · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4
효능 ORR 11.1%임상시험 2상태 ACTIVE
ADCBiologicstaleNational Cancer Institute (NCI)Phase 1

Brachyury-TRICOM (Brachyury-TRICOM)

Breast Cancer; Triple Negative Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 2상태 DISCONTINUED
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Preclinical

CAR-CLD18 T Cells (CAR-CLD18 T Cells)

Advanced Gastric Adenocarcinoma; Pancreatic Adenocarcinoma · Advanced Gastric Adenocarcinoma

#AdvancedGastricAdenocarcinoma#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 2상태 ACTIVE
CGTBiologicstaleAutolus LimitedPhase 2

CAR-T cells targeting CD19 and CD22 (CAR-T cells targeting CD19 and CD22)

B-Cell Acute Lymphoblastic Leukemia, Adult · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 2상태 RECRUITING
CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 2

CAR-T infusion (CAR-T infusion)

Refractory Metastatic Colorectal Cancer · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 67%임상시험 2상태 ACTIVE
CGTBiologicstaleThe Beijing Pregene Science and…Phase 2

CART-19 cells (CART-19 cells)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 43.8%임상시험 2상태 ACTIVE
CGTBiologicstaleAthenex, Inc.Phase 1

CD19 CAR T-cell (CD19 CAR T-cell)

Membranous Nephropathy; Lupus Nephritis (LN) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 67%임상시험 2상태 RECRUITING
CGTBiologicstaleTimmune Biotech Inc.Phase 1

CD19-TriCAR-T/SILK (CD19-TriCAR-T/SILK)

Non-Hodgkin Lymphoma of Intestine; Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 94%임상시험 2상태 ACTIVE
CGTBiologicstaleEssen BiotechPhase 2

CD19/BCMA CAR T-cells (CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Lupus Nephritis · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleOneChain ImmunotherapeuticsPhase 1

CD1a-CAR T (CD1a-CAR T)

T-cell Acute Lymphoblastic Leukemia; Lymphoblastic T-Cell Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
CGTBiologicstaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 2상태 DISCONTINUED
CGTBiologicstaleGyala TherapeuticsPhase 1

CD84-CART (CD84-CART)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING

66 / 209 페이지

← 이전다음 →